Cipher Surgical® was established in 2010 to develop OpClear® from its proof of principle. The company received a CE mark for a prototype OpClear® in October 2013 and after extensive clinical evaluations in the UK, the device was redesigned in 2015 to optimise its performance. OpClear® is patented and cleared for sale in Europe and selected markets.
The company’s head office is in Coventry and ISO 13485 accredited manufacturing is outsourced in the UK.
Significant investors include Angel Co Fund and a fund managed by Midven Ventures, and the company’s shares are EIS qualifying.